Core Insights - ONWARD Medical N.V. successfully raised EUR 50.85 million through an accelerated bookbuild offering, issuing 11.3 million new ordinary shares at an issue price of EUR 4.50 per share [1][2][3] Group 1: Financial Details - The private placement was supported by existing and new investors, including Ottobock SE & Co. KGaA as a cornerstone investor and healthcare specialist investor Invus [2][6] - The net proceeds from the private placement are expected to provide cash runway through at least the end of 2026, assuming no drawdown of the company's debt facility [4][6] Group 2: Use of Proceeds - The company plans to allocate the net proceeds as follows: 40% for development initiatives including product development and clinical studies for the investigational ARC-IM® System, 30% to expand sales and operations for the ARC-EX® System, 20% to support quality and administrative activities, 5% for working capital, and 5% to cover financing costs [7] Group 3: Market Position and Future Plans - ONWARD Medical is transitioning to a commercial-stage company, validated by strong demand for its ARC-EX® System, and plans to use the raised capital to expand commercial activities and advance its pipeline [3][10] - The new shares are expected to be listed on Euronext Brussels, Euronext Amsterdam, and Euronext Paris on October 28, 2025 [8]

Core Insights - ONWARD Medical N.V. successfully raised EUR 50.85 million through an accelerated bookbuild offering, issuing 11.3 million new ordinary shares at an issue price of EUR 4.50 per share [1][2][5] Company Overview - ONWARD Medical is a leading neurotechnology company focused on therapies to restore movement and function in individuals with spinal cord injuries and other movement disabilities [10][11] - The company has developed the ARC Therapy and has received 10 Breakthrough Device designations from the FDA for its technologies [10] Investment Details - The private placement was supported by existing and new investors, including Ottobock SE & Co. KGaA as a cornerstone investor and healthcare specialist investor Invus [2][5] - The net proceeds from the private placement are expected to extend the company's cash runway through at least the end of 2026 [4][5] Use of Proceeds - The funds will be allocated as follows: - 40% for product development, clinical studies, and regulatory activities for the investigational ARC-IM System - 30% to expand sales and operations for the commercialization of the ARC-EX System - 20% to support quality and administrative activities - 5% for working capital and general corporate purposes - 5% to cover financing costs, including existing debt obligations [6] Market Activity - Trading of ONWARD Medical's shares was temporarily suspended during the bookbuilding period and is set to resume on October 24, 2025 [7] - The new shares are expected to be listed on Euronext Brussels, Euronext Amsterdam, and Euronext Paris on October 28, 2025 [8]